Background & relevance

The treatment algorithm has drastically changed the last years. As recent as 2017, second-line therapy for mUCa was either: re-exposure to first-line platinum-based therapy, vinflunine, taxane, best supportive care or clinical study. Luckily, times have changed.

Regulatory approval status of drugs for mUCa (status 1 July 2022)

CPS: combined positive score